Aerosolized Bexarotene Inhibits Lung Tumorigenesis without Increasing Plasma Triglyceride and Cholesterol Levels in Mice

Department of Surgery, Washington University School of Medicine, St Louis, MO 63110, USA.
Cancer Prevention Research (Impact Factor: 5.27). 02/2011; 4(2):270-6. DOI: 10.1158/1940-6207.CAPR-10-0246
Source: PubMed

ABSTRACT Prior studies have shown the retinoid X receptor (RXR) agonist bexarotene has preventive efficacy in rodent models of mammary and lung tumorigenesis albeit causing hypertriglyceridemia and hypercholesterolemia. We reasoned that bexarotene delivered by inhalation may provide sufficient dose directly to the respiratory tract to achieve efficacy while avoiding these side effects. In this study, the chemopreventive activity of aerosolized bexarotene was investigated in the benzo(a)pyrene [B(a)P]-induced mouse lung tumor model as assessed by tumor multiplicity and tumor load. Aerosolized bexarotene significantly decreased tumor multiplicity and tumor load by 43% and 74%, respectively. Our data showed that bexarotene can both inhibit proliferation and promote apoptosis in vivo. Our data also show that aerosolized bexarotene did not increase plasma total cholesterol and triglyceride level compared with diet group. These results indicate that aerosolization may be a safe and effective route of administering bexarotene for chemoprevention of lung cancer.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Insulin-like growth factor-1 receptor (IGF-1R) is a transmembrane heterotetramer that is activated by Insulin-like growth factor 1 and is crucial for tumor transformation and survival of malignant cells. Importantly, IGF-1R overexpression has been reported in many different cancers, implicating this receptor as a potential target for anticancer therapy. Picropodophyllin (PPP) is a potent inhibitor of IGF-1R and has antitumor efficacy in several cancer types. However, the chemopreventive effect of PPP in lung tumorigenesis has not been investigated. In this study, we investigated the chemopreventive activity of PPP in a mouse lung tumor model. Benzo(a)pyrene was used to induce lung tumors, and PPP was given by nasal inhalation to female A/J mice. Lung tumorigenesis was assessed by tumor multiplicity and tumor load. PPP significantly decreased tumor multiplicity and tumor load. Tumor multiplicity and load were decreased by 52% and 78% respectively by 4 mg/ml aerosolized PPP. Pharmacokinetics analysis showed good bioavailability of PPP in lung and plasma. Treatment with PPP increased staining for cleaved caspase-3 and decreased Ki-67 in lung tumors, suggesting that the lung tumor inhibitory effects of PPP were partially through inhibition of proliferation and induction of apoptosis. In human lung cancer cell lines, PPP inhibited cell proliferation, and also inhibited phosphorylation of IGF-1R downstream targets, AKT and MAPK, ultimately resulting in increased apoptosis. PPP also reduced cell invasion in lung cancer cell lines. In view of our data, PPP merits further investigation as a promising chemopreventive agent for human lung cancer. © 2014 Wiley Periodicals, Inc.
    Molecular Carcinogenesis 08/2014; DOI:10.1002/mc.22206 · 4.77 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Bexarotene (Bex) is a synthetic retinoid that exhibits anti-tumor activities. However, the low solubility of the compound hinders its development. In this study, bexarotene nanocrystal was developed and its surface was modified to improve the dissolution and absorption of the drug. The nanocrystals were prepared via precipitation, high-pressure homogenization method, and modified by folate-chitosan (FA-CS), which relied on the charge interaction between the negatively charged nanocrystals and the positively charged FA-CS. The physical-chemical properties in terms of particle size, size distribution, zeta potential, morphology and crystallinity were evaluated. The results showed that bexarotene nanocrystals with surface modification by folate-chitosan conjugates (FC-NC-Bex) with a mean particle size of 631.3 ± 2.7 nm, a polydispersity index of 0.33 ± 0.06 and a zeta potential of 24.6 ± 1.9 mV was obtained. The result of differential scanning calorimetry (DSC) showed that the nanocrystals were still in crystalline state after the preparation procedure. In the in vitro dissolution test, FC-NC-Bex showed significant increase in dissolution rate compared to raw bexarotene (nearly 6.5-fold). Compared to bexarotene suspension, FC-NC-Bex exhibited significant increase in AUC0-∞ (approximately 3-fold) and Cmax (about 1.5-fold). Taken together, the results suggested that FC-NC-Bex may provide a potential opportunity in enhancing the dissolution rate of bexarotene and its gastrointestinal absorption.
    Drug Delivery 04/2014; DOI:10.3109/10717544.2014.904455 · 2.20 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Bexarotene (Targretin(®)) is a synthetic retinoid that selectively activates the retinoid X receptor subfamily of retinoid receptors and exhibits potent antitumor activity. However, the poor solubility and bioavailability limit its application. The main aim of this study is to investigate the potential of oral and parenteral nanocrystals in enhancing the bioavailability of bexarotene. In this work, the orthogonal design was used to screen the optimum stabilizers and precipitation-combined microfluidization method was employed to obtain the optimal nanocrystals. According to DSC, X-ray diffraction analysis and Raman examination, the nanocrystals were still in crystalline state after the preparation procedure. By reducing the particle size, the in vitro dissolution rate of bexarotene was increased significantly. The in vivo test was carried out in rats and pharmacokinetic parameters of the bexarotene solution and bexarotene nanocrystals were compared after gavage and intravenous administration. The higher AUC and lower Cmax indicated that oral bexarotene nanocrystals significantly increased the bioavailability of bexarotene and decreased its side effects. Compared to the oral nanocrystals, the intravenous nanocrystals cut losses and increased bioavailability because of the absence of first pass effect and enterohepatic circulation.
    European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 12/2013; DOI:10.1016/j.ejpb.2013.12.005 · 4.25 Impact Factor